Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged relMore >>

Stock Quote OREX (Common Stock) Exchange NASDAQ (US Dollar) Financial Status Indicator D Price $2.40 Change (%)   0.05 (2.04%) Volume 66,965 Jul 25, 2017 4:00 p.m. ET Minimum 20 minute delay Refresh quote

Recent News

More >>

Date Title   07/25/17 Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2017 Financial Results on August 8, 2017 07/10/17 Orexigen Announces Presentation of Data for OREX-1019 and OREX-1038, Preclinical Candidates for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioid Drug Addiction 05/16/17 Orexigen Announces Activities at European Congress on Obesity 2017 05/09/17 Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.